Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
|
Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
|
Common stock No Par Value [Member] |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Total |
| Beginning balance, value at Nov. 30, 2019 |
|
|
$ 3,806
|
$ 36,848,063
|
$ (38,578,232)
|
$ (1,726,363)
|
| Beginning balance, shares at Nov. 30, 2019 |
|
|
14,688,726
|
|
|
|
| Common shares issued for the acquisition of Supera Pharmaceuticals, Inc. a company under common control |
|
|
|
|
(605,089)
|
(605,089)
|
| Common Shares Issued For Acquisition Value, Shares |
|
|
13,096,640
|
|
|
|
| Effect of the adoption of Topic 842 effective as of January 1, 2019 |
|
|
|
|
(1,379)
|
(1,379)
|
| Ending balance, value at Dec. 31, 2019 |
|
|
$ 3,806
|
36,848,063
|
(39,184,700.00)
|
(2,332,831.00)
|
| Ending balance, shares at Dec. 31, 2019 |
|
|
27,785,366
|
|
|
|
| Private placement of common shares |
|
|
|
650,000
|
|
650,000
|
| Private placement of common shares, shares |
|
|
250,835
|
|
|
|
| Net loss |
|
|
|
|
(981,949)
|
(981,949)
|
| Ending balance, value at Mar. 31, 2020 |
|
|
$ 3,806
|
37,498,063
|
(40,166,649)
|
(2,664,780)
|
| Ending balance, shares at Mar. 31, 2020 |
|
|
28,036,201
|
|
|
|
| Beginning balance, value at Dec. 31, 2019 |
|
|
$ 3,806
|
36,848,063
|
(39,184,700.00)
|
(2,332,831.00)
|
| Beginning balance, shares at Dec. 31, 2019 |
|
|
27,785,366
|
|
|
|
| Net loss |
|
|
|
|
|
(5,199,758)
|
| Ending balance, value at Sep. 30, 2020 |
|
|
$ 3,806
|
40,614,836
|
(44,384,458)
|
(3,765,816)
|
| Ending balance, shares at Sep. 30, 2020 |
|
|
28,551,379
|
|
|
|
| Beginning balance, value at Mar. 31, 2020 |
|
|
$ 3,806
|
37,498,063
|
(40,166,649)
|
(2,664,780)
|
| Beginning balance, shares at Mar. 31, 2020 |
|
|
28,036,201
|
|
|
|
| Stock based compensation for services |
|
|
|
14,800
|
|
14,800
|
| Stock based compensation for services, shares |
|
|
1,930
|
|
|
|
| Stock options issued for debt issuance |
|
|
|
693,450
|
|
693,450
|
| Net loss |
|
|
|
|
(1,094,909)
|
(1,094,909)
|
| Ending balance, value at Jun. 30, 2020 |
|
|
$ 3,806
|
38,206,313
|
(41,261,558)
|
(3,051,439)
|
| Ending balance, shares at Jun. 30, 2020 |
|
|
28,038,131
|
|
|
|
| Private placement of common shares |
|
|
|
1,330,000
|
|
1,330,000
|
| Private placement of common shares, shares |
|
|
513,248
|
|
|
|
| Stock options issued for debt issuance |
|
|
|
$ 273,935
|
|
$ 273,935
|
| Stock options issued for services |
|
|
|
804,588
|
|
804,588
|
| Net loss |
|
|
|
|
$ (3,122,900)
|
$ (3,122,900)
|
| Ending balance, value at Sep. 30, 2020 |
|
|
$ 3,806
|
40,614,836
|
(44,384,458)
|
(3,765,816)
|
| Ending balance, shares at Sep. 30, 2020 |
|
|
28,551,379
|
|
|
|
| Beginning balance, value at Dec. 31, 2020 |
|
|
$ 4,004
|
43,411,487
|
(48,672,525)
|
(5,257,034)
|
| Beginning balance, shares at Dec. 31, 2020 |
|
|
28,553,307
|
|
|
|
| Reverse merger with Akers Biosciences Inc effective April 16, 2021 |
|
|
|
|
|
|
| Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement |
|
|
|
|
|
|
| Exercise of prepaid equity forward contracts for common stock |
|
|
|
|
|
|
| Exercise of prepaid equity forward contracts for common stock, shares |
|
|
|
|
|
|
| Common shares issued for the acquisition of Supera Pharmaceuticals, Inc. a company under common control |
|
|
|
|
|
|
| Common Shares Issued For Acquisition Value, Shares |
|
|
|
|
|
|
| Effect of the adoption of Topic 842 effective as of January 1, 2019 |
|
|
|
|
|
|
| Stock based compensation for services |
|
|
|
|
|
|
| Stock based compensation for services, shares |
|
|
|
|
|
|
| Exercise of warrants for common stock |
|
|
|
|
|
|
| Exercise of warrants for common stock, shares |
|
|
|
|
|
|
| Net loss |
|
|
|
|
$ (3,089,704)
|
$ (3,089,704)
|
| Ending balance, value at Mar. 31, 2021 |
|
|
$ 4,004
|
43,411,487
|
(51,762,229)
|
(8,346,738)
|
| Ending balance, shares at Mar. 31, 2021 |
|
|
28,553,307
|
|
|
|
| Beginning balance, value at Dec. 31, 2020 |
|
|
$ 4,004
|
43,411,487
|
(48,672,525)
|
(5,257,034)
|
| Beginning balance, shares at Dec. 31, 2020 |
|
|
28,553,307
|
|
|
|
| Net loss |
|
|
|
|
|
(26,649,321)
|
| Ending balance, value at Sep. 30, 2021 |
$ 144,524
|
101,069,246
|
|
|
(75,321,846)
|
25,891,924
|
| Ending balance, shares at Sep. 30, 2021 |
72,992
|
|
37,419,774
|
|
|
|
| Beginning balance, value at Mar. 31, 2021 |
|
|
$ 4,004
|
43,411,487
|
(51,762,229)
|
(8,346,738)
|
| Beginning balance, shares at Mar. 31, 2021 |
|
|
28,553,307
|
|
|
|
| Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares |
72,992
|
|
8,335,627
|
|
|
|
| Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement |
|
15,036,051
|
|
|
|
15,036,051
|
| Exercise of prepaid equity forward contracts for common stock |
|
|
|
|
|
|
| Exercise of prepaid equity forward contracts for common stock, shares |
|
|
466,716
|
|
|
|
| Net loss |
|
|
|
|
(18,092,336)
|
(18,092,336)
|
| Reverse merger with Akers Biosciences Inc effective April 16, 2021 |
144,524
|
85,748,325
|
(4,004)
|
(43,411,487)
|
|
42,477,358
|
| Ending balance, value at Jun. 30, 2021 |
$ 144,524
|
100,784,376
|
|
|
(69,854,565)
|
31,074,335
|
| Ending balance, shares at Jun. 30, 2021 |
72,992
|
|
37,355,650
|
|
|
|
| Stock based compensation for services |
|
90,002
|
|
|
|
90,002
|
| Stock based compensation for services, shares |
|
|
16,826
|
|
|
|
| Exercise of warrants for common stock |
|
194,868
|
|
|
|
194,868
|
| Exercise of warrants for common stock, shares |
|
|
47,298
|
|
|
|
| Net loss |
|
|
|
|
(5,467,281)
|
(5,467,281)
|
| Ending balance, value at Sep. 30, 2021 |
$ 144,524
|
$ 101,069,246
|
|
|
$ (75,321,846)
|
$ 25,891,924
|
| Ending balance, shares at Sep. 30, 2021 |
72,992
|
|
37,419,774
|
|
|
|